N-tert-Butyl-N'-phenyl-sulfamid | 49689-92-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-tert-Butyl-N'-phenyl-sulfamid
• 英文别名: Cambridge id 5173872；N-(tert-butylsulfamoyl)aniline
• CAS: 49689-92-1
• 化学式: C₁₀H₁₆N₂O₂S
• 分子量: 228.315
• InChiKey: CRPMJBSCNGDMPD-UHFFFAOYSA-N

物化性质

• 沸点：
  332.5±25.0 °C(Predicted)
• 密度：
  1.212±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  66.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-tert-Butyl-N'-phenyl-sulfamid 在 三氟乙酸 作用下， 生成 N-(1-phenyl)sulfamide
  参考文献：
  名称：

  Trifluoroacetic acid cleavage of N-tert-butyl amides. New synthesis of primary sulfamides

  摘要：

  DOI：

  10.1021/jo00918a034
• 作为产物：
  描述：

  (2-甲基-2-丙基)氨磺酰氯化物 、 苯胺 在 三乙胺 作用下， 以 乙醚 为溶剂， 生成 N-tert-Butyl-N'-phenyl-sulfamid
  参考文献：
  名称：

  Trifluoroacetic acid cleavage of N-tert-butyl amides. New synthesis of primary sulfamides

  摘要：

  DOI：

  10.1021/jo00918a034

文献信息

• PLATELET ADP RECEPTOR INHIBITORS
  申请人：SCARBOROUGH ROBERT M.

  公开号：US20080194597A1

  公开（公告）日：2008-08-14

  Novel compounds of formulae (I) to (VIII), which more particularly include sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives which are effective platelet ADP receptor inhibitors. These derivatives may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also relates to a method for preventing or treating thrombosis in a mammal comprising the step of administering a therapeutically effective amount of a compound of formulae (I) to (VIII), or a pharmaceutically acceptable salt thereof.

  化合物的式子(I)到(VIII)，其中更特别地包括磺酰脲衍生物、磺酰硫脲衍生物、磺酰胍衍生物、磺酰氰胍衍生物、硫代酰基磺酰胺衍生物和酰基磺酰胺衍生物，这些衍生物是有效的血小板ADP受体抑制剂。这些衍生物可以用于各种制药组合物中，特别是对于预防和/或治疗心血管疾病，特别是与血栓形成有关的疾病非常有效。本发明还涉及一种预防或治疗哺乳动物血栓形成的方法，包括给予化合物的式子(I)到(VIII)或其药学上可接受的盐的治疗有效量。
• Fused-ring compounds, pharmaceutical composition and uses thereof
  申请人：SHANGHAI DE NOVO PHARMATECH CO., LTD.

  公开号：US10202388B2

  公开（公告）日：2019-02-12

  This disclosure is related to a fused-ring compound of formula (I) and/or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the fused ring compound of formula (I) and/or a pharmaceutically acceptable salt thereof, preparation methods thereof, and use thereof in modulating activity of indoleamine 2, 3-dioxygenase (IDO) and/or tryptophan 2, 3-dioxygenase (TDO). This disclosure further provides methods of treating IDO and/or TDO-associated diseases, including cancer, viral infection and autoimmune diseases.

  本公开涉及一种式(I)的熔环化合物和/或其药学上可接受的盐、一种包含式(I)的熔环化合物和/或其药学上可接受的盐的药物组合物、其制备方法以及其在调节吲哚胺2，3-二氧化酶(IDO)和/或色氨酸2，3-二氧化酶(TDO)活性中的用途。本公开进一步提供了治疗IDO和/或TDO相关疾病的方法，包括癌症、病毒感染和自身免疫性疾病。
• FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF
  申请人：SHANGHAI DE NOVO PHARMATECH CO., LTD.

  公开号：US20180022752A1

  公开（公告）日：2018-01-25

  This disclosure is related to a fused-ring compound of formula (I) and/or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the fused ring compound of formula (I) and/or a pharmaceutically acceptable salt thereof, preparation methods thereof, and use thereof in modulating activity of indoleamine 2, 3-dioxygenase (IDO) and/or tryptophan 2, 3-dioxygenase (TDO). This disclosure further provides methods of treating IDO and/or TDO-associated diseases, including cancer, viral infection and autoimmune diseases.
• US7622474B2
  申请人：——

  公开号：US7622474B2

  公开（公告）日：2009-11-24
• Trifluoroacetic acid cleavage of N-tert-butyl amides. New synthesis of primary sulfamides
  作者：John D. Catt、W. Lesley Matier

  DOI：10.1021/jo00918a034

  日期：1974.2